Leuven-based Coultreon Biopharma, formerly known as Onco3R Therapeutics, has closed a USD 125 million Series A financing round to advance its immunology pipeline, anchored by the oral SIK3 inhibitor COL-5671.
Sofinnova Investments led the round, with Forbion and Novo Holdings serving as co-leads. Additional participants included Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. The company said proceeds will support clinical advancement of COL-5671, with Phase II trials in psoriasis and ulcerative colitis planned, and a clinical proof-of-concept readout targeted for 2027. No previous financing rounds were disclosed beyond a seed investment from Galapagos in April 2025, which coincided with the transfer of full ownership of COL-5671 from Galapagos to Coultreon.
COL-5671, formerly designated O3R-5671 during its time at Galapagos, is a highly selective, oral once-daily inhibitor of salt-inducible kinase 3 (SIK3). Coultreon's scientific rationale centers on more than 15 years of research into the SIK family of proteins, which regulate key inflammatory pathways. The company has identified SIK3 as a driver of pathogenic immune signaling, and COL-5671 is designed to reduce transcription of pro-inflammatory cytokines including TNFα and IL-23 while increasing expression of the immunoregulatory cytokine IL-10. The company said early clinical and preclinical data have demonstrated favorable pharmacokinetics with once-daily dosing, sustained cytokine suppression, and a toxicology-supported safety profile. Target indications include ulcerative colitis, Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. COL-5671 is currently in Phase I studies.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article